Cite
HARVARD Citation
Kim, D. et al. (n.d.). Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. Lung cancer. pp. S30-S31. [Online].